TITLE

Prognostic significance of cyclooxygenase-2(COX-2) and expression of cell cycle inhibitors p21 and p27 in human pleural malignant mesothelioma

AUTHOR(S)
Baldi, A.; Santini, D.; Vasaturo, F.; Santini, M.; Vicidomini, G.; Marino, M. Pia. Di; Esposito, V.; Groeger, A. M.; Liuzzi, G.; Vincenzi, B.; Tonini, G.; Piccoli, M.; Baldi, F.; Scarpa, S.
PUB. DATE
May 2004
SOURCE
Thorax;May2004, Vol. 59 Issue 5, p428
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: A study was undertaken to analyze the potential prognostic value of the immunohistochemical expression of cyclooxygenase-2 (COX-2) and p27 in 29 malignant mesotheliomas already screened for the expression of p21 and p53. Methods: Immunohistochemistry was used to determine the expression of COX-2 and p27. The correlation with survival of these factors and of p21 and p53 expression was assessed by univariate and multivariate analyses. Results: A positive statistically significant correlation was found between p2? and p21 expression (p<0.0001), but there was a negative correlation between COX-2 expression and both p27 (p=0.001) and p21 (p<0.0001). No statistically significant correlation was recorded between p53 and all the other immunohistochemical parameters. Univariate analysis showed that overall survival was strongly influenced by p21, p27, and COX-2 expression, but multivariate Cox regression analysis showed that the only immunohistochemical parameter to influence overall survival of patients with mesothelioma was COX-2. Conclusions: These findings suggest that COX-2 expression may be a useful prognostic parameter for mesothelioma.
ACCESSION #
13372514

 

Related Articles

  • CD90 Is a Diagnostic Marker to Differentiate Between Malignant Pleural Mesothelioma and Lung Carcinoma With Immunohistochemistry. Kiyoko Kawamura; Kenzo Hiroshima; Takeo Suzuki; Kuan Chai; Naoto Yamaguchi; Masato Shingyoji; Toshikazu Yusa; Yuji Tada; Yuichi Takiguchi; Koichiro Tatsumi; Hideaki Shimada; Masatoshi Tagawa // American Journal of Clinical Pathology;Oct2013, Vol. 140 Issue 4, p544 

    Objectives: To pathologically distinguish mesothelioma from lung carcinoma, particularly adenocarcinoma. Methods: We conducted immunohistochemical analyses on clinical specimens, including 26 cases of mesothelioma, 28 cases of lung adenocarcinoma, and 33 cases of lung squamous cell carcinoma....

  • Immunohistochemical Profile of Paratesticular Serous Papillary Adenocarcinoma and Tunica Vaginalis Facilitates Distinction From Malignant Mesothelioma. Anchala, Praveen R.; Dhir, Rajiv; Parwani, Anil V.; Zynger, Debra L. // International Journal of Surgical Pathology;Sep2011, Vol. 19 Issue 5, p692 

    Testicular and paratesticular tumors resembling mullerian epithelium of the ovary are extremely uncommon. This study reports a case of paratesticular serous papillary adenocarcinoma (SPA) in an 87-year-old man that was misdiagnosed as malignant mesothelioma (MM) and is 37 years older than...

  • The role of folate receptor alpha (FRalpha) in the response of malignant pleural mesothelioma to pemetrexed-containing chemotherapy. Nutt, J. E.; Razak, A. R. A.; O'Toole, K.; Black, F.; Quinn, A. E.; Calvert, A. H.; Plummer, E. R.; Lunec, J. // British Journal of Cancer;2/10/2010, Vol. 102 Issue 3, p553 

    Background: The standard treatment of choice for malignant pleural mesothelioma is chemotherapy with pemetrexed and platinum, but the clinical outcome is poor. This study investigates the response to pemetrexed in a panel of eight mesothelioma cell lines and the clinical outcome for...

  • Utility of immunohistochemical analysis for cyclo-oxygenase 2 in the differential diagnosis of osteoblastoma and osteosarcoma. Hosono, Ako; Yamaguchi, Umio; Makimoto, Atsushi; Endo, Makoto; Watanabe, Atsuko; Shimoda, Tadakazu; Kaya, Mitsunori; Matsumura, Tadaki; Sonobe, Hiroshi; Kusumi, Tomomi; Yamaguchi, Takehiko; Hasegawa, Tadashi // Journal of Clinical Pathology;Apr2007, Vol. 60 Issue 4, p410 

    Aims: To study the immunoexpression of cyclo-oxygenase (COX) 2 in osteoblastomas (OBs) and osteosarcomas (OSs), and to assess the utility of immunohistochemical analysis for COX 2 in the differential diagnosis of the two tumour forms. Methods: The immunohistochemical features of COX 2 were...

  • Right extrapleural pneumonectomy for malignant mesothelioma via median sternotomy or thoracotomy?: Short- and long-term results Edwards, John G.; Martin-Ucar, Antonio E.; Stewart, Duncan J.; Waller, David A. // European Journal of Cardio-Thoracic Surgery;May2007, Vol. 31 Issue 5, p759 

    Abstract: Objective: To examine the short- and long-term results of right extrapleural pneumonectomy (EPP) for malignant pleural mesothelioma (MM) via median sternotomy or thoracotomy. Methods: We analysed the results of EPP in consecutive patients with early stage MM undergoing a radical...

  • Solitary Fibrous Tumor of the Larynx. Dotto, Jorge E.; Ahrens, William; Lesnik, David J.; Kowalski, Diane; Sasaki, Clarence; Flynn, Stuart // Archives of Pathology & Laboratory Medicine;Feb2006, Vol. 130 Issue 2, p213 

    Solitary fibrous tumors are relatively rare mesenchymal neoplasms that were originally described as pleural- or peritoneal-based lesions. Although they were considered a form of mesothelioma, subsequent investigation failed to reveal mesothelial differentiation. Characterization of their...

  • COX-2 is strongest predictor of early death in malignant mesothelioma.  // Journal of Clinical Pathology;Jul2004, Vol. 57 Issue 7, p686 

    This article presents a study reports suggesting that cyclooxygenase-2 (COX-2) is the strongest predictor of early death in malignant mesothelioma. New findings confirm how malignant mesothelioma develops, as COX-2 expression has been shown as a strong indicator of poor survival independently of...

  • Lung Cancer.  // Current Medical Literature: Respiratory Medicine;2006, Vol. 20 Issue 3, p86 

    The article comments on several researches about lung cancer. These include the "Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma," which have measured mesothelin amount in the sera and pleural fluid from 74 patients with mesothelioma, 35 patients with...

  • Immunohistochemistry of Pulmonary and Pleural Neoplasia. Beasley, Mary Beth // Archives of Pathology & Laboratory Medicine;Jul2008, Vol. 132 Issue 7, p1062 

    Context.-The use of immunohistochemical stains has several applications in the evaluation of pulmonary and pleural neoplasms. The number of available immunohistochemical stains is continually expanding and, although these stains are an important diagnostic adjunct, their use is not without...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics